
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
, “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
, “Use of statins is associated with an increased risk of rheumatoid arthritis”, Ann Rheum Dis, vol. 71, pp. 648-54, 2012.
, “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
, “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
, “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
, “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
, “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
, “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
, “Use of incretin agents and risk of pancreatic cancer: a population-based cohort study”, Diabetes Obes Metab, vol. 18, pp. 258-65, 2016.
, “Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 401-411, 2017.
, “Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture”, Bone, vol. 68, pp. 124-30, 2014.
, “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
, “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
, “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
, “Statin treatment and reduced risk of pneumonia in patients with diabetes”, Thorax, vol. 61, pp. 957-61, 2006.
, “Smoke-free legislation and the incidence of paediatric respiratory infections and wheezing/asthma: interrupted time series analyses in the four UK nations”, Sci Rep, vol. 5, p. 15246, 2015.
, “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
, “A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis”, Neurology, vol. 79, pp. 922-8, 2012.
, “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
, “The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink”, J Thromb Haemost, vol. 12, pp. 444-51, 2014.
, “The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010”, Osteoporos Int, vol. 25, pp. 2555-63, 2014.
, “Risk of infections in patients with gout: a population-based cohort study”, Sci Rep, vol. 7, p. 1429, 2017.
, “Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study”, Bmj, vol. 354, p. i3625, 2016.
, “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
, “Risk of fracture in patients with muscular dystrophies”, Osteoporos Int, vol. 25, pp. 509-18, 2014.
, “The risk of fracture in patients with multiple sclerosis: the UK general practice research database”, J Bone Miner Res, vol. 26, pp. 2271-9, 2011.
, “Risk of fracture in patients with Guillain-Barre syndrome”, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
, “Risk of fracture in patients with Charcot-Marie-Tooth disease”, Muscle Nerve, vol. 50, pp. 919-24, 2014.
, “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
, “The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity”, Diabetes Care, vol. 38, pp. 495-502, 2015.
, “Risk of cataract and glaucoma in patients with multiple sclerosis”, Mult Scler, vol. 18, pp. 628-38, 2012.
, “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
, “Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom”, JAMA Surg, vol. 150, pp. 1126-33, 2015.
, “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
, “Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs”, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
, “Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density”, Ann Rheum Dis, vol. 75, pp. 2095-2100, 2016.
, “Patterns of risk of cancer in patients with metal-on-metal hip replacements versus other bearing surface types: a record linkage study between a prospective joint registry and general practice electronic health records in England”, PLoS One, vol. 8, p. e65891, 2013.
, “The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation”, J Thromb Haemost, vol. 11, pp. 107-15, 2013.
, “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
, “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
, “Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study”, Bone, vol. 66, pp. 171-7, 2014.
, “Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 421-428, 2017.
, “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
, “Insulin glargine use and breast cancer risk: Associations with cumulative exposure”, Acta Oncol, vol. 55, pp. 851-8, 2016.
, “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
, “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
, “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
, “The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism”, PLoS One, vol. 11, p. e0148349, 2016.
, “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
,